Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
Cancer Research
|
October 3, 2008
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia
Holly M Horton, Matthew J Bernett, Erik Pong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2016
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
Uwe Reusch, Kimberly H Harrington, Chelsea J Gudgeon, et al.
Mabs
|
January 30, 2025
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity
Jeremy Loyau, Thierry Monney, Marco Montefiori, et al.
Frontiers in Immunology
|
May 8, 2023
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
Emilia Rabia, Véronique Garambois, Christine Dhommée, et al.
Nature Cancer
|
September 11, 2024
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Laura Carretero-Iglesia, Olivia J Hall, Jérémy Berret, et al.
Science (New York, N.Y.)
|
September 27, 2003
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
Paul M Steed, Malú G Tansey, Jonathan Zalevsky, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
Cancer Research
|
October 3, 2008
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia
Holly M Horton, Matthew J Bernett, Erik Pong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2016
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
Uwe Reusch, Kimberly H Harrington, Chelsea J Gudgeon, et al.
Mabs
|
January 30, 2025
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity
Jeremy Loyau, Thierry Monney, Marco Montefiori, et al.
Frontiers in Immunology
|
May 8, 2023
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
Emilia Rabia, Véronique Garambois, Christine Dhommée, et al.
Nature Cancer
|
September 11, 2024
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Laura Carretero-Iglesia, Olivia J Hall, Jérémy Berret, et al.
Science (New York, N.Y.)
|
September 27, 2003
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants
Paul M Steed, Malú G Tansey, Jonathan Zalevsky, et al.
Page
of 2